Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: Correlation with clinical behaviour [3]

British Journal of Haematology

Volumn 134, Issue 3, 2006, Pages 341-343

  Ma, W ^a   Kantarjian, H ^b   Verstovsek, S ^b   Jilani, I ^a   Gorre, M ^a   Giles, F ^b   Cortes, J ^b   O'Brien, S ^b   Keating, M ^b   Albitar, M ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Essential thrombocythemia; Idiopathic myelofibrosis; JAK2; Mutations; Polycythemia vera

Indexed keywords

AMINO ACID SUBSTITUTION; GENE; HUMAN; JAK2 GENE; LETTER; MYELOID METAPLASIA; MYELOPROLIFERATIVE DISORDER; POINT MUTATION; POLYCYTHEMIA VERA; PRIORITY JOURNAL; THROMBOCYTHEMIA;

GENOTYPE; HUMANS; JANUS KINASE 2; MYELOPROLIFERATIVE DISORDERS; POINT MUTATION; PROTEIN-TYROSINE KINASES; PROTO-ONCOGENE PROTEINS; SURVIVAL RATE;

EID: 33745635723     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06174.x     Document Type: Letter

References (6)

1. Albitar, M., Do, KA., Johnson, MM., Giles, FJ., Jilani, I., O'Brien, S., Cortes, J., Thomas, D., Rassenti, LZ., Kipps, TJ., Kantarjian, HM. & Keating, M. (2004) Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer, 101, 999-1008.
2. Baxter, EJ., Scott, LM., Campbell, PJ., East, C., Fourouclas, N., Swanton, S., Vassiliou, GS., Bench, AJ., Boyd, EM., Curtin, N., Scott, MA., Erber, WN. & Green AR; Cancer Genome Project (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. The Lancet, 365, 1054-1061.
3. James, C., Ugo, V., Le Couedic, JP., Staerk, J., Delhommeau, F., Lacout, C., Garcon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., Villeval, JL., Constantinescu, SN., Casadevall, N. & Vainchenker, W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434, 1144-1148.
4. Kralovics, R., Passamonti, F., Buser, AS., Teo, SS., Tiedt, R., Passweg, JR., Tichelli, A., Cazzola, M. & Skoda, RC. (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. New England Journal of Medicine, 352, 1779-1790.
5. Levine, RL., Wadleigh, M., Cools, J., Ebert, BL., Wernig, G., Huntly, BJ., Boggon, TJ., Wlodarska, I., Clark, JJ., Moore , S., Adelsperger, J., Koo, S., Lee, JC., Gabriel, S., Mercher, T., D'Andrea, A., Frohling, S., Dohner, K., Marynen, P., Vandenberghe, P., Mesa, RA., Tefferi, A., Griffin, JD., Eck, MJ., Sellers, WR., Meyerson, M., Golub, TR., Lee, SJ. & Gilliland, DG. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 7, 387-397.
6. Rogers, A., Joe, Y., Manshouri, T., Dey, A., Jilani, I., Giles, F., Estey, E., Freireich, E., Keating, M., Kantarjian, H. & Albitar, M. (2004) Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia. Blood, 103, 2799-2801.